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Abstract
Objective: Determine whether a treatment effect of ibudilast on brain atrophy
rate differs between participants with primary (PPMS) and secondary (SPMS)
progressive multiple sclerosis. Background: Progressive forms of MS are both
associated with continuous disability progression. Whether PPMS and SPMS
differ in treatment response remains unknown. Design/Methods: SPRINT-MS
was a randomized, placebo-controlled 96-week phase 2 trial in both PPMS
(n = 134) and SPMS (n = 121) patients. The effect of PPMS and SPMS phenotype on the rate of change of brain atrophy measured by brain parenchymal
fraction (BPF) was examined by fitting a three-way interaction linear-mixed
model. Adjustment for differences in baseline demographics, disease measures,
and brain size was explored. Results: Analysis showed that there was a threeway interaction between the time, treatment effect, and disease phenotype
(P < 0.06). After further inspection, the overall treatment effect was primarily
driven by patients with PPMS (P < 0.01), and not by patients with SPMS
(P = 0.97). This difference may have been due to faster brain atrophy progression seen in the PPMS placebo group compared to SPMS placebo (P < 0.02).
Although backward selection (P < 0.05) retained age, T2 lesion volume, RNFL,
and longitudinal diffusivity as significant baseline covariates in the linear-mixed
model, the adjusted overall treatment effect was still driven by PPMS
(P < 0.01). Interpretation: The previously reported overall treatment effect of
ibudilast on worsening of brain atrophy in progressive MS appears to be driven
by patients with PPMS that may be, in part, because of the faster atrophy progression rates seen in the placebo-treated group.

doi: 10.1002/acn3.51251
a

Investigators are listed in Supplemental
Appendix 1.

Introduction
We previously reported1 a significant reduction in the
rate of cerebral atrophy progression as determined by
brain parenchymal fraction (BPF) assessments in people

with progressive multiple sclerosis (MS) in a randomized
phase 2 clinical trial, “SPRINT-MS,” comparing ibudilast
to placebo. Detailed results of the MRI outcomes from
the SPRINT-MS trial were recently reported.2 Despite
recognition as different clinical disease phenotypes,3
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primary progressive (PPMS) and secondary progressive
(SPMS) are often viewed as being more similar than different pathologically.4 Little is known about whether these
disease phenotypes differ in treatment response.5
The phase 2 trial of ibudilast included people with both
PPMS and SPMS in roughly equal proportions using the
same inclusion and exclusion criteria, thus facilitating the
possibility to learn whether there were differences in
treatment response outcomes between these two MS phenotypes. We hypothesized that ibudilast would have had
a similar treatment effect in PPMS and SPMS.

Methods
SPRINT-MS (clinicaltrials.gov NCT01982942) was a randomized, placebo-controlled 96-week phase 2 trial that
evaluated the effect of ibudilast on brain measures of
integrity in both PPMS (n = 134) and SPMS (n = 121)
patients. Details of the trial design, imaging and statistical
methodology, and main results have been published.1,6
MRIs were acquired every 6 months; no gadolinium was
administered. Human subject protection was provided by
the NeuroNEXT central institutional review board at
Massachusetts General Hospital.
Analyses for this manuscript focus on the differential
effect of PPMS and SPMS clinical phenotypes on the
treatment effect as measured by BPF decline. In the primary analyses of the SPRINT-MS trial, the treatment
effect was estimated as the difference in the rate of BPF
decline between treatment groups. Differential treatment
effect then refers to the difference in treatment effect
across PPMS and SPMS disease phenotypes.
Similarly to the model in the original report,1 the differential treatment effect of PPMS and SPMS on the
rate of change of brain atrophy measured by BPF was
examined by fitting a linear-mixed model with a threeway interaction of disease phenotype, treatment, and
time with adjustment for immunomodulating therapy
use. A random intercept and slope were included to
account for the correlation between measurements and
an unstructured covariance structure was assumed. The
model also assumed a common intercept across treatment groups. The comparison of interest was a contrast
of the treatment effect between PPMS and SPMS phenotypes. All analyses were based on a modified intention-to-treat approach which included all patients
randomized to receive treatment and who also had at
least one post-randomization MRI assessment to measure BPF.
Models adjusting for differing baseline demographics
and disease measures between the MS phenotypes were
explored. A backward selection model (P < 0.05 as the
cut-off for inclusion) was also fit including all covariates
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that differed between the disease phenotypes at baseline.
Additional analyses were performed to assess the impact
of baseline brain size. Data were divided into “big” v.
“small” brains using the overall median baseline BPF.
Separate linear-mixed models were fit for each disease
type and the differential treatment effect between brain
sizes was estimated within each MS phenotype. Alternatively, we also fit separate models for big and small brains
and compared the effect of MS phenotype on the estimated treatment effect within each brain size.
In addition, we examined whether a differential treatment effect existed for short and long disease duration
within each disease phenotype. We categorized patients
into short and long disease duration based on the studywide
median
baseline
disease
duration
(median = 10 years). Patients with disease duration less than
or equal to 10 years were considered to have a “short”
disease duration and patients with the disease over
10 years were termed to have a “long” disease duration.
We then fit separate models for each disease phenotype
including a three-way interaction of time, treatment, and
disease duration (short vs. long) along with adjustment
for immunotherapy. Within each disease phenotype
model, we estimated the treatment effect for short and
long disease duration and the difference in effects.
In further exploratory analyses, differences in treatment
effect between disease phenotypes for the major secondary
outcome measures (cortical thickness (CTh); magnetization transfer ratio (MTR) in normal-appearing brain tissue,
transverse diffusivity and longitudinal diffusivity as measured by diffusion tensor imaging (DTI) of the pyramidal
tract, and retinal nerve fiber layer (RNFL) as measured by
optical coherence tomography) were analyzed using a
three-way interaction model. A similar analysis was conducted with a different whole brain atrophy measure
SIENA.7,8 All statistical analyses were performed in SAS 9.4
Software (SAS Institute, Cary, NC). Since these were
exploratory analyses, adjustment for multiplicity was not
conducted.

Results
Baseline demographics and disease
characteristics
The randomized population included 134 participants
with PPMS and 121 with SPMS. Their demographic and
disease characteristics are shown in Table 1. Notably,
there were significant differences in the following baseline
characteristics: Expanded Disability Status Scale (EDSS);
25-foot walk; T2 lesion volume; retinal nerve fiber layer
(RNFL) thickness; pyramidal tract diffusion tensor imaging longitudinal diffusivity (LD); and BPF.
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Table 1. Baseline demographic and disease characteristics by disease phenotype.
PPMS
(n = 134)

Characteristic
Age (yrs), mean (SD)
Females, n (%)
Race
Caucasian, n (%)
Black/ African American, n (%)
Other, n (%)
Unknown/Not Reported, n (%)
Hispanic/Latino, n (%)
Ibudilast, n (%)
use of im therapy, n (%)
Glatiramer Acetate, n (%)
Interferon-beta, n (%)
disease duration (yrs), median (min, max)
Expanded Disability Status Scale, median (min, max)5
25-foot walk (sec), median (min, max)
9-hole peg test (sec), median (min, max)
Symbol Digit Modality Test (number correct), mean (SD)
Low contrast visual acuity test (number correct), mean (SD)7
Brain parenchymal fraction (unitless), mean (SD)
T2 Lesion volume (cm3), mean (SD)
median (min, max)
Magnetization transfer ratio in normal-appearing brain tissue (normalized units),
mean (SD)8
Cortical thickness (mm), mean (SD)
Diffusion tensor imaging, longitudinal diffusivity
(10-3 mm2/sec), mean (SD)
Diffusion tensor imaging, transverse diffusivity
(10-3 mm2/sec), mean (SD)
Retinal nerve fiber layer thickness (µm), mean (SD)9

55.24 (6.93)
57 (42.54%)
124
5
3
2
3
68
31
21
10
6
6.0
8.13
28.73
42.41
29.53
0.8087
8.46
4.05
0.34

(92.54%)
(3.73%)
(2.24%)
(1.49%)
(2.24%)
(50.75%)
(23.13%)
(15.67%)
(7.46%)
(0, 34)
(2.5, 6.5)
(3.60, 75.30)
(16.58, 167.75)
(13.88)
(12.21)
(0.0262)
(10.80)
(0.03, 55.80)
(0.25)

SPMS
(n = 121)
56.17 (7.64)
79 (65.29%)
112
6
1
2
4
61
49
22
27
16
6.0
11.60
30.75
42.71
26.27
0.7988
12.44
9.28
0.26

(92.56%)
(4.96%)
(0.83%)
(1.65%)
(3.31%)
(50.41%)
(40.50%)
(18.18%)
(22.31%)
(1, 41)
(3.0, 7.0)
(4.05, 180.00)
(17.83, 201.88)
(14.88)
(13.02)
(0.0323)
(11.17)
(0.11, 47.47)
(0.30)

Pvalue1
0.31
<0.01
1.002

0.713
0.96
<0.014

<0.016
<0.016
<0.016
0.086
0.87
0.04
0.01
<0.01
<0.016
0.03

3.0846 (0.1951)
1.23 (0.05)

2.9759 (0.2450)
1.25 (0.05)

<0.01
0.01

0.55 (0.04)

0.56 (0.05)

0.10

85.31 (12.03)

78.50 (11.03)

<0.01

1

The P-value for continuous variables was based on Student’s t-test, unless specified otherwise. The P-value for nominal variables was based on a
chi-square test, unless specified otherwise.
2
The P-value for Caucasians vs. Non-Caucasians was based on Fishers exact test.
3
The P-value for Hispanics vs. Non-Hispanics was based on Fishers exact test.
4
The P-value compares use of IM therapy vs untreated.
5
Scores on the Expanded Disability Status scale range from 0.0 to 10.0, with higher scores indicating worse disability. For study eligibility, scores
had to be within 3.0-6.5 (inclusive). One subject was enrolled with a score below the required level. A protocol deviation was entered and the
subject was kept in the study.
6
The P-value was based on a Wilcoxon Rank Sum Test.
7
Data were not available for 1 patient in the PPMS group and 1 patient in the SPMS group.
8
Data were not available for 3 patients in the PPMS group.
9
Data were not available for 2 patients in the PPMS group and 7 patients in the SPMS group.

Differential effect of ibudilast on whole
brain atrophy
Our analysis showed that there was a three-way interaction between the time, treatment effect, and disease phenotype (P < 0.06). The overall ibudilast treatment effect
was primarily driven by patients with PPMS (P < 0.01)
[estimated difference between ibudilast and placebo
within PPMS, 0.00166, 95% CI (0.0005, 0.00281)], and
not by patients with SPMS (P = 0.97) [estimated

difference between ibudilast and placebo within SPMS,
0.00002, 95% CI ( 0.00121, 0.00125)] (Table 2).
Baseline covariates were evaluated to see whether they
accounted for the apparent lack of efficacy on BPF in
SPMS versus PPMS. In a backward selection model
(P < 0.05) retaining age, T2 lesion volume, RNFL, and
LD as significant baseline covariates, the test of differing
treatment effect between PPMS and SPMS was P = 0.07
[estimated differing treatment effect, 0.0016, 95% CI
( 0.00014, 0.0034) (Table 3)]. Therefore, after accounting
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Table 2. Annualized rates of change in BPF estimates by disease phenotype with 95% CI according to PPMS vs. SPMS . (1 study year is
defined as 48 weeks).
Estimated rate of BPF
change
(95% CI)
Disease
Phenotype
Overall

PPMS1

SPMS1

Ibudilast

Placebo

Estimated
difference
in rate of
change
(95% CI)

0.00097
( 0.00157,
0.00036)
0.00088
( 0.00171,
0.00005)
0.00106
( 0.00193,
0.00019)

0.00186
( 0.00245,
0.00126)
0.00254
( 0.00334,
0.00173)
0.00108
( 0.00195,
0.00022)

0.000890
(0.000041,
0.001738)
0.00166
(0.00050,
0.00281)
0.00002
( 0.00121,
0.00125)

P-value for
difference in
rate of
change
<0.04

0.97

Estimated rates of change by disease type based on model that
included a three-way interaction of time, treatment, and disease type
using all modified intention-to-treat subjects.

for these covariates, the adjusted overall treatment effect
was still driven principally by the PPMS cohort
(P < 0.01) [estimated difference between ibudilast and
placebo within PPMS, 0.00165, 95% CI (0.000459,
0.00283)]. Similar results were obtained from models that
adjusted for baseline covariates one at a time.

Differential rate of cerebral atrophy (BPF)
by disease phenotype
PPMS placebo patients had a significantly faster rate of
BPF decline than SPMS placebo patients over 48 weeks
(p < 0.02) (Table 4; Figure 1).

Table 3. Annualized rates of change in BPF estimates by disease phenotype adjusted for baseline covariates with 95% CI according to
PPMS vs. SPMS. (1 study year is defined as 48 weeks).

Disease
Phenotype

PPMS1
SPMS1

1

Ibudilast

Placebo

0.00079
( 0.00164,
0.000067)
0.00112
( 0.00204,
0.00019)

0.00243
( 0.00326,
0.00161)
0.00115
( 0.00205,
0.00026)

Estimated
difference
in rate of
change
(95% CI)
0.001646
(0.000459,
0.002833)
0.000037
( 0.00125,
0.001322)

P-value for
difference in
rate of
change
<0.01

0.95

Estimated rates of change by disease phenotype from a model
adjusted for baseline T2 lesion volume, retinal nerve fiber thickness,
longitudinal diffusivity, and age.
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Estimated rate of BPF
decline over 48 weeks
(95% CI)
PPMS placebo
patients
SPMS placebo
patients
Difference
(PPMS – SPMS)

0.00254 ( 0.00334,

0.00173)

0.00108 ( 0.00195,

0.00022)

0.00146 ( 0.00264,

0.00027)

P-value

<0.02

<0.01

1

Estimated rate of BPF
change
(95% CI)

Table 4. Differential rate of cerebral atrophy (BPF) by disease phenotype in placebo group.

Effect of baseline brain size
The SPMS group had evidence of more parenchymal tissue loss at baseline. Because we were not able to control
for a baseline BPF, when BPF was the outcome measure,
we sought to evaluate a potential effect of baseline brain
size by analyzing small versus large brains. Subjects were
categorized into small or large brains based on the studywide median baseline BPF (Figure 2). Separate linearmixed models’s for BPF over time among those with
small or large brains at baseline were fit for PPMS and
SPMS subjects. Within each disease phenotype model, we
included a three-way interaction of time, treatment, and
brain size along with adjustment for immunotherapy. We
tested whether there was a differential treatment effect
(ibudilast versus placebo) for large versus small brain
sizes within each disease phenotype.
There was not a significantly different treatment effect
for large versus small brains within either disease phenotype (primary progressive: estimate of difference over 1
year = 0.00012, 95% CI [ 0.00255, 0.00232], P-value =
0.92; for secondary progressive: estimate of difference over
1 year = 0.00089, 95% CI [ 0.00151, 0.00329], P-value =
0.47).
In a second analysis, we fit separate linear-mixed models in those above versus below median BPF and evaluated for three-way interaction (time, treatment, disease
phenotype). There was no differential treatment effect for
disease phenotype within either brain size (P = 0.13 for
patients below median BPF, and P = 0.31 for patients
above median BPF). Within each brain size, the difference
in rate of BPF decline between treatment groups was larger in the PPMS patients than in the SPMS patients. In
patients whose baseline BPF was below the median value,
the treatment effect was not significant in either disease
phenotype. In patients whose baseline BPF was above the
median value the treatment effect was significant in PPMS
patients (P = 0.02) but not in SPMS patients (P = 0.5).
In a third analysis, we evaluated the effect of short vs
long disease duration. For PPMS patients, the estimated
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Figure 1. The estimated rate of change in cerebral atrophy (assessed by BPF) in patients receiving ibudilast or placebo by disease phenotype.

treatment effect for long disease duration (n = 31, or
24.41%) was 0.00265, 95% CI [0.00028, 0.00501],
P = 0.0282 and short disease duration (n = 31, or
26.50%) was 0.00124, 95% CI [ 0.00014, 0.00263], Pvalue = 0.0785, P = 0.0785. There was no difference in
the treatment effect for long vs short disease duration:
0.00141, 95% CI [ 0.00133, 0.00415], P = 0.3137. For
SPMS patients, the estimated treatment effect for long
disease duration was 0.00065, 95% CI [ 0.00072,
0.00201], P = 0.3546 and short disease duration was
0.00153, 95% CI [ 0.00386, 0.00080], P = 0.1978.
There was no difference in the treatment effect for long
vs short disease duration: 0.00218, 95% CI [ 0.00053,
0.00488], P = 0.1146.
The original trial’s analysis model assumed an unstructured covariance matrix for the random effects (subjectspecific random intercepts and slopes) while maintaining
independent errors within a subject given the random
effects. To keep alignment with that original analysis
model we used the same specifications for this report’s
primary analysis. In an exploratory analysis, we fit a more

parsimonious three-way interaction model. For a model
with only a random intercept, the estimated interaction
effect of this model was 0.0016, 95% CI (0.0004, 0.0028),
P = 0.0115. The estimated treatment effect of ibudilast
versus placebo within PPMS was 0.0017, 95% CI (0.0009,
0.0025), P < 0.0001 and within SPMS was 0.0001, 95%
CI ( 0.0008, 0.0010), P = 0.7938. These results were similar to the primary analysis.

Differential effect of ibudilast on major
secondary outcome
Cortical thickness declined by 0.00861 mm more per year
in the placebo group relative to the ibudilast group,
P < 0.01. The three-way test for interaction indicated treatment effect was not differentiated by disease phenotype
(P = 0.37), although was directionally consistent with that
seen with BPF. For completeness, we estimated the treatment effect within each disease phenotype as we did for
BPF. Results were similar to the BPF analyses: the treatment
effect appeared more pronounced in the PPMS group than
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Figure 2. Baseline brain atrophy as measured by BPF, according to brain size. Blue = placebo; red = ibudilast treatment.
Table 5. Annualized1 rates of change in CTh (mm) estimates by disease phenotype.
Estimated rate of CTh
change
(95% CI)
Disease
Phenotype
Overall

PPMS

SPMS

Ibudilast

Placebo

0.00192
( 0.00607,
0.00223)
0.000193
( 0.00554,
0.005925)
0.00424
( 0.01026,
0.001784)

0.01053
( 0.01459,
0.00648)
0.01094
( 0.01649,
0.00540)
0.01003
( 0.01598,
0.00408)

Estimated
difference
in rate of
change
(95% CI)
0.00861
(0.00283,
0.01440)
0.01114
(0.003178,
0.01910)
0.005790
( 0.00266,
0.01424)

P-value for
difference in
rate of
change
<0.01

<0.01

0.18

1

1 study year is defined as 48 weeks.

in the SPMS group (Table 5). Similarly, the three-way test
for interaction was directionally consistent but not statistically significant for normal-appearing brain tissue MTR
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(P = 0.44), pyramidal tract longitudinal diffusivity
(P = 0.70), and retinal nerve fiber layer (p = 0.77), but not
for pyramidal tract transverse diffusivity (data not shown).

Discussion
The impetus to study ibudilast in progressive MS derived
from the trial of ibudilast in relapsing MS.9 Although that
study failed to demonstrate an effect on the focal inflammatory pathology characteristic of relapsing disease, the
favorable effects observed on brain atrophy suggested a
neuroprotective effect.
Prior to the publication of standardized definitions of
the MS phenotypes that described SPMS and PPMS in
1996,3 no distinction was recognized between MS with
gradually worsening neurological function, whether there
had been relapsing activity at the outset of the disease
(SPMS) or not (PPMS). More recently, some reports have
suggested biological differences between these clinically
determined disease phenotypes, and others have not.4
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Examples of therapies demonstrating beneficial responses
in brain atrophy in progressive MS phenotypes include
siponimod10 and simvastatin11 (not a registered therapy
for MS) in SPMS and ocrelizumab12 in PPMS. In contrast, fingolimod was not found to slow the progression
of brain atrophy in PPMS.13 Since these trials assessed
treatment effect in separate clinical phenotypes, it remains
unclear whether differential treatment effects occur
between these phenotypes.5
We performed a post hoc analysis of SPRINT-MS data
to assess whether the previously reported1 treatment effect
of ibudilast was similar in PPMS and SPMS. The results
of this analysis suggest that the response to treatment
observed in the BPF atrophy outcome within the PPMS
group and not the SPMS group is driving the overall
ibudilast-related treatment difference. This difference held
when the variables that were significantly different
between the groups at baseline (age, LD, RNFL, T2 lesion
volume, EDSS and 25-foot walk) were accounted for in
the model. Baseline brain size did not account for the
PPMS versus SPMS difference, nor did it have a measurable influence on treatment effect.
We also evaluated the effect of disease duration (short
vs. long). This model’s estimate suggests that disease
duration does not explain the differential effect in treatment by disease phenotype. If disease duration was a
driving factor, we would expect that PPMS subjects with
longer disease duration would exhibit a lesser or no treatment effect of ibudilast and SPMS subjects with shorter
disease duration would have a greater treatment effect.
The results suggested the opposite: the estimated treatment effect for PPMS patients with long disease duration
did not differ from short disease duration. In fact, the
estimated effect was larger, albeit not statistically significantly. The estimated treatment effect for SPMS patients
with short disease duration did not differ from long disease duration: the estimated effect for short disease duration suggested ibudilast had a lower effect, but was not
statistically significant.
We also explored an alternative methodology for the
assessment of cerebral atrophy using the SIENA method
to assess change in total brain size over the course of the
trial. We found a similar pattern of differential effect
although this did not reach statistical significance. In
addition, the initial trial results showed an overall reduction in the rate of cortical thickness loss,1 and we again
found a similar pattern according to phenotype: this
effect was principally driven by the PPMS subjects.
Results of conventional imaging outcomes are reported in
a separate publication.2
To our knowledge, the differential treatment effect on
brain atrophy that we observed between SPMS and PPMS
has not been described previously. Interestingly, there was

Treatment Response by Progressive MS Phenotype

a significantly higher rate of atrophy progression in PP
versus SP MS seen in the placebo arm similar to the pattern observed in the literature.14 We believe that this
could account, at least in part, for our observations.
Another possible explanation is that the PPMS phenotype
was more susceptible to a specific treatment effect of
ibudilast because of a more active disease process manifest as an approximately double rate of atrophy progression compared to SPMS. Since this was a post hoc
exploratory analysis, additional investigation is warranted
to assess the reproducibility and generalizability of these
results. Furthermore, the clinical relevance of these imaging findings needs to be evaluated. If confirmed and
found to be clinically relevant, these findings will need to
be considered in future trial designs for progressive MS.
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